XML 31 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Information (Tables)
 9 Months Ended
Sep. 30, 2020
Segment Information [Abstract]  
Segment Information

The following tables show our segment revenue and income (loss) from operations for the three and nine months ended September 30, 2020 and 2019 (in thousands), respectively.

Three Months Ended September 30, 2020
  
Ionis Core
    
Akcea
Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
74,171
    
$
—
    
$
—
    
$
74,171
  
Product sales, net
    
—
      
19,040
      
—
      
19,040
  
Licensing and other royalty revenue
    
2,975
      
—
      
(846
)
    
2,129
  
Total commercial revenue
    
77,146
      
19,040
      
(846
)
    
95,340
  
R&D revenue under collaborative agreements
    
64,309
      
430
      
—
      
64,739
  
Total segment revenue
  
$
141,455
    
$
19,470
    
$
(846
)
  
$
160,079
  
Total operating expenses
  
$
129,657
    
$
69,283
    
$
(2,324
)
  
$
196,616
  
Loss from operations
  
$
11,798
    
$
(49,813
)
  
$
1,478
    
$
(36,537
)

Three Months Ended September 30, 2019
  
Ionis Core
    
Akcea
Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
81,672
    
$
—
    
$
—
    
$
81,672
  
Product sales, net
    
—
      
11,945
      
—
      
11,945
  
Licensing and other royalty revenue
    
1,946
      
136
      
—
      
2,082
  
Total commercial revenue
    
83,618
      
12,081
      
—
      
95,699
  
R&D revenue under collaborative agreements
    
69,165
      
8,543
      
(5,515
)
    
72,193
  
Total segment revenue
  
$
152,783
    
$
20,624
    
$
(5,515
)
  
$
167,892
  
Total operating expenses
  
$
119,147
    
$
53,215
    
$
(6,993
)
  
$
165,369
  
Income (loss) from operations
  
$
33,636
    
$
(32,591
)
  
$
1,478
    
$
2,523
  

Nine Months Ended September 30, 2020
  
Ionis Core
    
Akcea
Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
211,925
    
$
—
    
$
—
    
$
211,925
  
Product sales, net
    
—
      
50,562
      
—
      
50,562
  
Licensing and other royalty revenue
    
8,809
      
—
      
(2,261
)
    
6,548
  
Total commercial revenue
    
220,734
      
50,562
      
(2,261
)
    
269,035
  
R&D revenue under collaborative agreements
    
167,870
      
7,358
      
(5,280
)
    
169,948
  
Total segment revenue
  
$
388,604
    
$
57,920
    
$
(7,541
)
  
$
438,983
  
Total operating expenses
  
$
396,259
    
$
204,084
    
$
(11,944
)
  
$
588,399
  
Loss from operations
  
$
(7,655
)
  
$
(146,164
)
  
$
4,403
    
$
(149,416
)

Nine Months Ended September 30, 2019
  
Ionis Core
    
Akcea
Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
Revenue:
                        
Commercial revenue:
                        
SPINRAZA royalties
  
$
211,884
    
$
—
    
$
—
    
$
211,884
  
Product sales, net
    
—
      
28,563
      
—
      
28,563
  
Licensing and other royalty revenue
    
8,466
      
6,172
      
(3,000
)
    
11,638
  
Total commercial revenue
    
220,350
      
34,735
      
(3,000
)
    
252,085
  
R&D revenue under collaborative agreements
    
294,512
      
176,328
      
(94,007
)
    
376,833
  
Total segment revenue
  
$
514,862
    
$
211,063
    
$
(97,007
)
  
$
628,918
  
Total operating expenses
  
$
355,437
    
$
256,152
    
$
(87,900
)
  
$
523,689
  
Income (loss) from operations
  
$
159,425
    
$
(45,089
)
  
$
(9,107
)
  
$
105,229
  


The following table shows our total assets by segment at September 30, 2020 and December 31, 2019 (in thousands), respectively.

Total Assets
  
Ionis Core
    
Akcea
Therapeutics
    
Elimination of
Intercompany Activity
    
Total
  
September 30, 2020
  
$
3,436,990
    
$
507,977
    
$
(849,266
)
  
$
3,095,701
  
December 31, 2019
  
$
3,478,081
    
$
599,250
    
$
(844,219
)
  
$
3,233,112